| Gene symbol | KRAS | Synonyms | C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras, K-Ras 2, KI-RAS, KRAS1, KRAS2, NS, NS3, OES, RALD, RASK2, c-Ki-ras, c-Ki-ras2 | Type of gene | protein-coding |
| Chromosome | 12 | Map location | 12p12.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | KRAS proto-oncogene, GTPase | ||||
| GTO ID | GTC3641 |
| Trial ID | NCT06105021 |
| Disease | Pancreatic Ductal Adenocarcinoma | Non-Small Cell Lung Cancer | Colorectal Cancer |
| Altered gene | KRAS |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | AFNT-211 |
| HLA | HLA-A*11:01 |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor |
| Year | 2023 |
| Country | United States |
| Company sponsor | Affini-T Therapeutics, Inc. |
| Other ID(s) | AFNT211-22-101 |
| Cohort 1 | |||||||||||
|
|||||||||||